INSPECS Group Past Earnings Performance
Past criteria checks 0/6
INSPECS Group's earnings have been declining at an average annual rate of -25.8%, while the Medical Equipment industry saw earnings growing at 1.9% annually. Revenues have been growing at an average rate of 32.1% per year.
Key information
-25.8%
Earnings growth rate
-103.9%
EPS growth rate
| Medical Equipment Industry Growth | -9.5% |
| Revenue growth rate | 32.1% |
| Return on equity | -4.0% |
| Net Margin | -2.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Lacklustre Performance Is Driving INSPECS Group plc's (LON:SPEC) 29% Price Drop
Dec 10
INSPECS Group plc's (LON:SPEC) Revenues Are Not Doing Enough For Some Investors
Sep 17Is INSPECS Group (LON:SPEC) A Risky Investment?
Jun 09INSPECS Group plc (LON:SPEC) Surges 27% Yet Its Low P/S Is No Reason For Excitement
May 04INSPECS Group plc's (LON:SPEC) Shares Lagging The Industry But So Is The Business
Jan 18A Look At The Intrinsic Value Of INSPECS Group plc (LON:SPEC)
Oct 30A Look At The Intrinsic Value Of INSPECS Group plc (LON:SPEC)
May 23Returns On Capital At INSPECS Group (LON:SPEC) Paint A Concerning Picture
Mar 04A Look At The Fair Value Of INSPECS Group plc (LON:SPEC)
Feb 01INSPECS Group (LON:SPEC) Has A Pretty Healthy Balance Sheet
Dec 06INSPECS Group (LON:SPEC) Might Be Having Difficulty Using Its Capital Effectively
Nov 01Estimating The Intrinsic Value Of INSPECS Group plc (LON:SPEC)
Aug 13Is It Time To Consider Buying Inspecs Group plc (LON:SPEC)?
Jun 23Calculating The Fair Value Of Inspecs Group plc (LON:SPEC)
May 10The Inspecs Group (LON:SPEC) Share Price Is Up 92% And Shareholders Are Holding On
Mar 16What Type Of Shareholders Own The Most Number of Inspecs Group plc (LON:SPEC) Shares?
Feb 09A Look At The Fair Value Of Inspecs Group plc (LON:SPEC)
Dec 17Revenue & Expenses Breakdown
How INSPECS Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 195 | -4 | 99 | 0 |
| 31 Mar 24 | 199 | -3 | 100 | 0 |
| 31 Dec 23 | 203 | -1 | 101 | 0 |
| 30 Sep 23 | 205 | -1 | 102 | 0 |
| 30 Jun 23 | 207 | -1 | 103 | 0 |
| 31 Mar 23 | 204 | -4 | 102 | 0 |
| 31 Dec 22 | 201 | -6 | 100 | 0 |
| 30 Sep 22 | 207 | -5 | 102 | 0 |
| 30 Jun 22 | 204 | -4 | 100 | 0 |
| 31 Mar 22 | 192 | -4 | 91 | 0 |
| 31 Dec 21 | 182 | -4 | 84 | 0 |
| 30 Sep 21 | 149 | -4 | 67 | 0 |
| 30 Jun 21 | 113 | -4 | 49 | 0 |
| 31 Mar 21 | 74 | -5 | 33 | 0 |
| 31 Dec 20 | 35 | -7 | 17 | 0 |
| 30 Sep 20 | 37 | -6 | 17 | 0 |
| 30 Jun 20 | 38 | -5 | 16 | 0 |
| 31 Mar 20 | 44 | 0 | 16 | 0 |
| 31 Dec 19 | 46 | 5 | 15 | 0 |
| 30 Sep 19 | 50 | 6 | 15 | 0 |
| 30 Jun 19 | 48 | 6 | 14 | 0 |
| 31 Mar 19 | 45 | 4 | 13 | 0 |
| 31 Dec 18 | 45 | 3 | 13 | 0 |
| 31 Dec 17 | 36 | -2 | 14 | 0 |
| 31 Dec 16 | 18 | 1 | 6 | 0 |
Quality Earnings: SPEC is currently unprofitable.
Growing Profit Margin: SPEC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPEC is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.
Accelerating Growth: Unable to compare SPEC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPEC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (39.9%).
Return on Equity
High ROE: SPEC has a negative Return on Equity (-4.03%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 11:11 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
INSPECS Group plc is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Hall | Peel Hunt LLP |